M

Matinas BioPharma Holdings Inc
F:6LJ

Watchlist Manager
Matinas BioPharma Holdings Inc
F:6LJ
Watchlist
Price: 2.69 EUR Market Closed
Market Cap: 674.7m EUR

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
€0
/
$0

Peer Comparison

Country Company Market Cap Operating
Margin
US
Matinas BioPharma Holdings Inc
AMEX:MTNB
4.1m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
154.2B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.3B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.6B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.9B USD
Loading...
No Stocks Found

Market Distribution

Not Available
No Country distribution data available for this multiple

Matinas BioPharma Holdings Inc
Glance View

Market Cap
674.7m EUR
Industry
Biotechnology

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 34 full-time employees. The company went IPO on 2014-06-03. The firm is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform) to maximize global clinical impact and patient access. The Company’s lead anti-fungal product candidate, MAT2203, is an application of its LNC Platform to a broad spectrum and potent anti-fungal drug called amphotericin B. Its second clinical-stage LNC-based product candidate is MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including NTM, as well as various multidrug-resistant gram-negative and intracellular bacterial infections. The company also has internal discovery programs ongoing in the formulation and delivery of small oligonucleotides, namely antisense oligonucleotides (ASOs) and silencing or short interfering RNAs (siRNAs).

6LJ Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top